Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 3,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
PXD101
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
West Hollywood, California • Bethesda, Maryland • Dallas, Texas
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Duarte, California • Sacramento, California • Tampa, Florida + 5 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
Entospletinib, Vincristine, Dexamethasone, CNS Prophylaxis
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Orange, California + 7 more
Conditions
Hairy Cell Leukemia
Interventions
BL22 (CAT-3888)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Blastic Phase, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Bortezomib, Laboratory Biomarker Analysis, Tipifarnib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Multiple Myeloma
Interventions
STI-6129
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Canton, Ohio
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab, Pharmacological Study
Other · Drug · Biological
Lead sponsor
Yvonne Efebera
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Interventions
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Andrew Yee, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
carboplatin, fludarabine phosphate, thalidomide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Interventions
4A10
Drug
Lead sponsor
Allterum Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
fludarabine and rituximab, fludarabine, rituximab, pixantrone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
8
States / cities
Muscle Shoals, Alabama • Oxnard, California • Jefferson City, Missouri + 5 more
Conditions
Richter's Transformation
Interventions
selinexor
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 4 more
Conditions
Solid Tumor, Lymphoma
Interventions
IMC-002
Biological
Lead sponsor
ImmuneOncia Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Diffuse Large Cell Lymphoma, Gray Zone Lymphoma, Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Hodgkin Lymphoma
Interventions
CPX-351
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 30 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
13
States / cities
Huntsville, Alabama • Tucson, Arizona • Duarte, California + 9 more
Conditions
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection
Interventions
VK-2019
Drug
Lead sponsor
Pierluigi Porcu
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Lymphoma, Non-Hodgkin
Interventions
CC-99282, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Portland, Oregon + 1 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Interventions
BXCL701
Drug
Lead sponsor
Eric Stephen Winer, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Myeloid Leukemia
Interventions
Fludarabine, Melphalan, vadastuximab talirine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 7 more
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Pembrolizumab
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas
Conditions
DLBCL, Richter Syndrome
Interventions
acalabrutinib, vistusertib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 130 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Fairway, Kansas • Bethesda, Maryland • Rochester, Minnesota + 4 more
Conditions
Lymphocytic Leukemia, Chronic, SLL
Interventions
CAP-100
Drug
Lead sponsor
Catapult Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Conditions
Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate, Prednisone, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Relapsed Hepatoblastoma, Refractory Hepatoblastoma
Interventions
Biospecimen collection
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
1
States / cities
Cincinnati, Ohio